BioSpace News Archive

EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, today announced that Daniel Wiegand, CEO, and Jonathan Rittichier, CSO, both co-founders of the company, will be participating in the 19th annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain, beginning October 22nd.

Nicox SA provided financial results for Nicox SA and its subsidiaries for the first half of 2023 and for the third quarter of 2023 and provided an update on key future milestones.

Ryvu Therapeutics announced that it entered into a Clinical Trial Financial Support agreement for an investigator initiated clinical trial with the European EMSCO network.

Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and Company.

BioCryst Pharmaceuticals, Inc. announced that the company will host an R&D Day at 1:00 p.m. ET on Friday, November 3, 2023, where the company plans to describe its drug discovery process and introduce additional therapies from its pipeline.

Oncolytics Biotech® Inc. announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter of 2023.

Covalon Technologies Ltd., an advanced medical technologies company, is pleased to announce that the Company’s Board of Directors has approved the grant of an aggregate of 295,000 deferred stock units to certain of its directors and officers.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new individual patient response data showing nearly all individuals (95%) treated with ZORYVE® (roflumilast) cream 0.3% had a measurable improvement in Psoriasis Area and Severity Index (PASI).

Three years from establishment Stramsen Biotech, Inc, one of the leading plant-based biotech start-up companies, is raising $10 million at a $807 million valuation according to a third-party valuation company based in Los Angeles, California - Stonebridge Advisory.

Enveric Biosciences announced that Joseph Tucker, Ph.D., Chief Executive Officer, will present at the Centurion One 5th Global Summit being held on October 24-25, 2023 in Nassau, Bahamas.